Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jelena Saillard"'
Autor:
Robert E. Litman, Kimberly E. Vanover, Dean F. Wong, Lorena Gapasin, Robert E. Davis, Michal Weingart, Yun Zhou, Weiguo Ye, Jelena Saillard, James Robert Brašić, Sharon Mates
Publikováno v:
Neuropsychopharmacology
Dopamine D2 receptor occupancy (D2RO) is a key feature of all currently approved antipsychotic medications. However, antipsychotic efficacy associated with high D2RO is often limited by side effects such as motor disturbances and hyperprolactinemia.
Autor:
Michal Weingart, Juan Sanchez, Saresh Durgam, Susan Kozauer, Andrew Satlin, Shawon Hossain, Sharon Mates, Robert C. Davis, Jelena Saillard, Kimberly E. Vanover, Steven Glass
BACKGROUND: Lumateperone (ITI-007) is an investigational drug for the treatment of schizophrenia, bipolar depression, agitation associated with dementia and other neuropsychiatric disorders. With a unique mechanism of action, lumateperone modulates s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce5543dd3d23362ac43581f9ddf5ab39
https://europepmc.org/articles/PMC6455296/
https://europepmc.org/articles/PMC6455296/
Autor:
Kimberly E. Vanover, Carol A. Tamminga, Robert E. Davis, Jelena Saillard, John M. Kane, Jeffrey A. Lieberman, Cedric O'Gorman, Sharon Mates, Christoph U. Correll, Michal Weingart
Publikováno v:
JAMA Psychiatry. 77:349
Importance Individuals living with schizophrenia are affected by cardiometabolic, endocrine, and motor adverse effects of current antipsychotic medications. Lumateperone is a serotonin, dopamine, and glutamate modulator with the potential to treat sc
Autor:
Robert E. Davis, Steven Glass, Jelena Saillard, Michal Weingart, Andrew Satlin, Sharon Mates, K.E. Vanover
Publikováno v:
Alzheimer's & Dementia. 14
Autor:
Juan Sanchez, Robert C. Davis, Kimberly E. Vanover, Susan Kozauer, Steven Glass, Andrew Satlin, Sharon Mates, Jelena Saillard, Michal Weingart
Publikováno v:
CNS Spectrums. 24:190-191
BackgroundLumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems. Lumateperone is a potent 5-HT2A antagonist, a mesolimbic/mesocortical dopamine p
Autor:
Christoph U. Correll, Alex Dmitrienko, Robert E. Davis, Michal Weingart, Kimberly E. Vanover, Steve Glass, Cedric O'Gorman, Sharon Mates, Jelena Saillard
Background: Schizophrenia affects about 1% of the population and exerts a great burden on patients and caregivers. Newer treatments are needed to provide broad symptom control and improved tolerability. Lumateperone is an investigational agent in lat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a661189402d8c563b01645920a2ff576
https://europepmc.org/articles/PMC5475480/
https://europepmc.org/articles/PMC5475480/
Autor:
Jelena Saillard, Steven Glass, Kimberly E. Vanover, Susan Kozauer, Michal Weingart, Andrew Satlin, Alex Dmitrienko, Sharon Mates, Christoph U. Correll, Robert C. Davis
Publikováno v:
Schizophrenia Bulletin
Background Lumateperone (ITI-007) is a first-in-class investigational agent in development for the treatment of schizophrenia. Acting synergistically through serotonergic, dopaminergic and glutamatergic systems, lumateperone represents a new approach
Autor:
Alex Dmitrienko, Susan Kozauer, Andrew Satlin, Robert L. Davis, Jelena Saillard, Steven Glass, Michal Weingart, Sharon Mates, Christoph U. Correll, Kimberly E. Vanover
Publikováno v:
Schizophrenia Bulletin
Background Lumateperone (ITI-007) is a first-in-class investigational agent in development for the treatment of schizophrenia. Acting synergistically through serotonergic, dopaminergic and glutamatergic systems, lumateperone represents a new approach
Autor:
Correll, Christoph U., Davis, Robert E., Weingart, Michal, Saillard, Jelena, O'Gorman, Cedric, Kane, John M., Lieberman, Jeffrey A., Tamminga, Carol A., Mates, Sharon, Vanover, Kimberly E.
Publikováno v:
JAMA Psychiatry; Apr2020, Vol. 77 Issue 4, p349-358, 10p
Publikováno v:
Neuropsychopharmacology; Dec2015 Supplement, Vol. 40, pS443-S611, 169p